Ikaria(R) Receives FDA Orphan Drug Designation For Inhaled Carbon Monoxide For Delayed Graft Function In Solid Organ Transplants

Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inhaled carbon monoxide for use in the reduction of the incidence and severity of delayed graft function (DGF) in patients undergoing solid organ transplantation. Ralf Rosskamp, M.D.

More: continued here

Filed under: Pharma Industry on July 31st, 2008